Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 15

Tiny brain circuit linked to cocaine withdrawal discomfort and relapse risk

Why do so many people relapse after quitting cocaine? A new study from The Hebrew University reveals that a specific “anti-reward” brain circuit becomes hyperactive during withdrawal—driving discomfort and pushing users back toward the drug. Surprisingly, this circuit may also serve as a built-in protective mechanism, offering new hope for addiction treatment.

Cocaine addiction has long been understood as a tug-of-war between reward and restraint. The rush of dopamine keeps users hooked, while withdrawal triggers anxiety, depression, and despair. But a new study by researchers at The Hebrew University of Jerusalem reveals that it’s not just the craving for pleasure—but the brain’s aversion to pain—that plays a powerful role in relapse.

Led by Prof. Yonatan M. Kupchik and Ph.D. student Liran Levi from the Faculty of Medicine, the study, appearing in Science Advances, identifies a specific “anti-reward” network deep in the brain that undergoes lasting changes during cocaine use, withdrawal, and re-exposure. This glutamatergic network, located in the ventral pallidum, is emerging as a key player in addiction—and a promising target for future therapies.

Quantum tool could lead to gamma-ray lasers and access the multiverse

A University of Colorado Denver engineer is on the cusp of giving scientists a new tool that can help them turn sci-fi into reality.

Imagine a safe gamma ray laser that could eradicate cancer cells without damaging healthy tissue. Or a tool that could help determine if Stephen Hawking’s multiverse theory is real by revealing the fabric underlying the universe.

Assistant Professor of Electrical Engineering Aakash Sahai, Ph.D., has developed a quantum breakthrough that could help those sci-fi ideas develop and has sent a ripple of excitement through the quantum community because of its potential to revolutionize our understanding of physics, chemistry, and medicine.

An Extra Sense May Connect Gut Bacteria With Our Brain

According to new research, communication between the gut and the brain is sophisticated enough to be classed as a new and distinct sense – one capable of affecting our appetite and even our mood.

This two-way link has previously been associated with a variety of health issues, though the physical processes at work have never been clearly identified.

Building on what we already know about our digestive and neurological systems, a team from Duke University in the US traced a series of biochemical actions from the digestive tracts of mice to their brains.

New Organ Recovery Technique Could Make More Heart Transplants Available

Vanderbilt University Medical Center researchers have developed a groundbreaking new method for the recovery of hearts from deceased organ donors after circulatory death (DCD). The method (rapid recovery with extended ultra-oxygenated preservation [REUP]), which involves flushing the donor heart with a cold oxygenated preservation solution after death, avoids the disadvantages of two existing preservation methods, both of which reanimate the heart, one that has ethical questions and another that

A Naked Mole Rat Gene Was Put Into Mice, And It Made Them Live Longer

Naked mole rats are well known for living far longer lives than any rodent ought to have. It’s just one of their amazing talents for surviving in a challenging, even hostile underground environment.

A fascinating new study led by researchers from the University of Rochester in the US has shown a single gene could play a significant role in their longevity, one that could be transferred into other mammals to give their own life spans a nudge.

The gene – a version of what’s known as hyaluranon synthase 2 – produces an abundance of high-molecular-mass hyaluronic acid (HMM-HA), a compound already thought to mediate the risk of cancer in naked mole rats (Heterocephalus glaber).

Targeting the ‘undruggable’: New molecular degraders offer hope for aggressive breast cancer

In the battle against aggressive breast cancer, a once-elusive target is now within reach—thanks to a breakthrough from a team from the Faculty of Medicine at Hebrew University. Dr. Raphael Benhamou and M.Sc. student Liann Kassabri have developed innovative druglike molecules capable of degrading HuR, a key RNA-binding protein that stabilizes oncogenes and fuels cancer progression.

HuR (also known as ELAVL1) has long been labeled “undruggable” due to its structural flexibility and lack of a conventional active site. Overexpressed in many cancer types—particularly breast cancer—HuR fortifies by protecting mRNAs that drive and survival.

“We knew that simply blocking HuR wasn’t enough,” says Dr. Benhamou. “We needed to eliminate it altogether.” Strikingly, this elimination led to a three to four orders of magnitude improvement in anticancer properties compared to traditional HuR-binding molecules that do not induce degradation.

Skin swabs may help detect Parkinson’s years before symptoms appear

Remote, scalable cognitive behavioral therapy–based chronic pain programs are effective for treating individuals with high-impact chronic pain.

Importance Cognitive behavioral therapy (CBT) skills training interventions are recommended first-line nonpharmacologic treatment for chronic pain, yet they are not widely accessible.

Objective To examine effectiveness of remote, scalable CBT-based chronic pain (CBT-CP) treatments (telehealth and self-completed online) for individuals with high-impact chronic pain, compared with usual care.

Design, Setting, and Participants This comparative effectiveness, 3-group, phase 3 randomized clinical trial enrolled 2,331 eligible patients with high-impact chronic musculoskeletal pain from 4 geographically diverse health care systems in the US from January 2021 through February 2023. Follow-up concluded in April 2024.

Feature: Cough medicine shows promise in treating Parkinson’s disease

An over-the-counter cough medicine may be the key to slowing the progression of Parkinson’s disease.

Called Ambroxol, the drug is commonly used to break up phlegm, but early studies have shown it can also prevent the build-up of misfolded clumps of protein in the brain, known as Lewy bodies – a hallmark of Parkinson’s and other types of dementia.

Robarts scientist Dr. Stephen Pasternak is leading a phase 2 clinical trial to further study Ambroxol’s potential as a disease-modifying drug.

“Current treatments for Parkinson’s target the symptoms of the disease, such as movement, but don’t change the long-term progression of pathology in the brain,” he explained. “We hope Ambroxol will be a disease-changing drug.”

Dr. Stephen Pasternak is leading a phase 2 clinical trial to study Ambroxol, an over-the-counter cough medicine, with the goal of slowing or stopping the progression of Parkinson’s Disease Dementia.

Mum says new diabetes drug would be ‘kind of magic’ if it works

A world-first human trial of a drug designed to treat the underlying cause of type 1 diabetes has begun in Australia.

Five patients with the condition have already been dosed as part of the trial, including mum-of-two Caecilie Wickstroem Giralde, who was diagnosed last year.

University of Queensland researcher Ranjeny Thomas has spent more than a quarter of a century developing the drug, designed to rebalance the body’s immune response in people with type 1 diabetes, which affects more than 130,000 Australians.

The immune system starts to recognise insulin-producing cells in the pancreas as something it needs to attack and destroy in people with type 1 diabetes — one of dozens of auto-immune diseases in which the body starts to attack itself.

Professor Thomas, who is based at UQ’s Frazer Institute, said the experimental drug — dubbed ASITI-201 — was designed to retrain the immune system so it no longer attacks the insulin-producing pancreatic cells, known as beta cells.

The drug, given as an injection under the skin, combines fragments of a protein found in the beta cells of people with type 1 diabetes and vitamin D to calm the immune response.

Continue reading “Mum says new diabetes drug would be ‘kind of magic’ if it works” | >

Will implantable brain-computer interfaces soon benefit people with motor impairments?

A review published in Advanced Science highlights the evolution of research related to implantable brain-computer interfaces (iBCIs), which decode brain signals that are then translated into commands for external devices to potentially benefit individuals with impairments such as loss of limb function or speech.

A comprehensive systematic review identified 112 studies, nearly half of which have been published since 2020. Eighty iBCI participants were identified, mostly participating in studies concentrated in the United States, but with growing numbers of studies from Europe, China, and Australia.

The analysis revealed that iBCI technologies are being used to control devices such as robotic prosthetic limbs and consumer .